drugset / Trial / NCT00345696
1stline Study Capecitabine Administered on Continuous Way Plus Oxaliplatin&Bevacizumab Every 2weeks in Metastatic CCR.
Phase 2
Completed
32 enrolled
Unidad Integral de Investigación en Oncología S.L.
Hoffmann-La Roche · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determinate progression free survival after 9 months of treatment.
Timeline
- Start
- 2006-06
- Primary completion
- 2008-10
- Completion
- 2011-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | Capecitabine | Small molecule | 600 mg/m2 | Oral |
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | Intravenous |